Mechanisms of action of extracorporeal photochemotherapy

Transfusion and Apheresis Science

Volumn 29, Issue 1, 2003, Pages 61-70

  Heshmati, F ^a  

^a Cochin Hospital ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOXSALEN;

ANTIGEN PRESENTING CELL; ANTIGENICITY; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL ACTIVATION; CELL DAMAGE; CELL DIFFERENTIATION; CELL MATURATION; CELLULAR IMMUNITY; CONFERENCE PAPER; CUTANEOUS T CELL LYMPHOMA; DENDRITIC CELL; DNA CROSS LINKING; DOWN REGULATION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HELPER CELL; HUMAN; IMMUNE RESPONSE; MONOCYTE; MONONUCLEAR CELL; NONHUMAN; PHAGOCYTOSIS; PHOTOCHEMOTHERAPY; PROTEIN DNA BINDING; SEZARY SYNDROME; TH1 CELL; TREATMENT INDICATION; ULTRAVIOLET A RADIATION;

EID: 0037623787     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-0502(03)00103-4     Document Type: Conference Paper

References (69)

1. Edelson R., Berger C., Gasparro F., Jegasothy B., Heald P., Wintroub B.et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N. Engl. J. Med. 316:1987;297-303.
2. Gilchrest B.A. Methoxalen photochimiotherapy for mycosis fungoides. Cancer Treat. Rep. 63:1979;663-667.
3. Heald P., Rook A., Perez M., Wintroub B., Knobler R., Jegasothy B.et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J. Am. Acad. Dermatol. 28(6):1993;1023-1024.
4. Menkes C.J., Andreu J., Heshmati F., Hillikquin P. Treatment of refractory rheumatoid arthritis by extracorporeal photochemotherapy. Br. J. Rheumatol. 31:1992;789-790.
5. Rook A.H., Freundich B., Jegasothy B.V., Perez M.I., Barr W.G., Jimenez S.A.et al. Treatment of systemic sclerosis with Extracorporeal photochemotherapy. Results of a multicenter trial. Arch. Dermatol. 128:1992;337-346.
6. Knobler R.M. Extracorporeal photochemotherapy for the treatment of lupus erythematosus: preliminary observations. Springer Semin. Immunopathol. 16:1994;323-325.
7. Rook A.H., Jgasothy B.V., Heald P.et al. Extracorporeal photochemotherapy for drug resistant pemphigus vulgaris. Ann. Intern. Med. 112:1990;303-305.
8. Bécherel P.A., Bussel A., Chosidow O., Rabian C., Piette I.C., Francès C. Extracorporeal photochemotherapy for chronic erosive lichen planus. Lancet. 351(9105):1998;805.
9. Barr M.L., Meiser B.M., Eisen H.J., Roberts R.F., Livi U., Dall'Amico R.et al. Photopheresis for the prevention of rejection in cardiac transplantation. NEJM. 339(24):1998;1744-1751.
10. Andreu G., Achkar A., Couetil J.P., Guillemain R., Heshmati F., Amrein C.et al. Extracorporeal photochemotherarpy treatment for acute lung rejection episode. J. Art. Lung Transplant1. 14:1995;793-796.
11. Heshmati F, Achkar A, Couetil JP, Rochemaure J, Andreu. Extracorporeal photochemotherapy (ECP) for the treatment of acute lung rejection (ALR) and bronchiolitis obliterans syndrom (BOS) after heart-lung (HLTX) or lung transplantation (LTX). Congrès de l'American Association of Blood Banks, Denver, October 1997.
12. Horina J.H., Mülleger R.R., Horn S., Holzer H., Halwachs G., Kerl H.et al. Photopheresis for renal allograft rejection. Lancet. 346:1995;61.
13. Dall'Amico R., Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther. Apher. 6(4):2002;296-304.
14. Edelson R.L. Transimmunization: science catches up to the clinical success. Transfus. Apheresis Sci. 26:2002;177-180.
15. Yoo E.K., Rook A.H., Elenitsas R., Gasparro F.P., Vewels B.R. Apoptosis induction of ultraviolet A and photochemotherapy in cutaneous T-cell lymphoma; relevance to mechanism of therapeuric action. J. Invest. Dermatol. 107:1996;235-242.
16. Berger C.L., Hanlon D., Kanada D., Girardi M., Edelson R.L. Transimmunization, a novel approach for tumor immunotherapy. Transfus. Apheresis Sci. 26:2002;205-216.
17. Gasparro F.P., Felli A., Schmitt M. Psoralen photobiology - the relationship between DNA damage, chromatin structure, transcription and immunogenetic effects. Recent Results Cancer Res. 143:1997;101-127.
18. Musajo L., Rodighiero G., Dall'Acqua F. Evidence of a photoreaction of a photosensitives furocoumarin with DNA and with pyrimidine nucleosides and nucleotide. Experientia. 21:1965;24-25.
19. Gasparro F.P., Berger C.L., Edelson R. Effect of monochromatic UVA light and 8 methoxypsoralen on human lymphocyte response to mitogen. Photodermatology. 1:1984;10-17.
20. Gasparro F.P., Dall'Amico R., Goldminz D., Simmons E., Weingold D. Molecular aspects of extracorporeal photochemotherapy. Yale J. Biol. Med. 62:1989;579-593.
21. Gasparro F.P., Felli A., Schmitt M. Psoralen photobiology - the relationship between DNA damage, chromatin structure, transcription and immunogenetic effects. Recent Results Cancer Res. 143:1997;101-127.
22. Veronese F., Schiavon O., Bevilacqua R. Photoconjugation of 8-methoxypsoralen with proteins. Photochem. Photobiol. 29:1979;1123-1127.
23. Joshi P.C., Pathak M. Production of singlet oxygen and superoxides radicals by psoralen and their biological significance. Biochem. Biophys. Res. Comm. 112:1983;638-646.
24. Cohen I.R. Regulation of auto-immune disease: Physiological and therapeutic. Immunol. Rev. 94:1986;5-21.
25. Ben Nun A., Wekerle H., Cohen I.R. Vaccination against autoimmune encephalomyeletis with T lymphocyte line cells reactive against myeline basic protein. Nature. 292:1981;60-61.
26. Berger C.L., Perez M., Laroche L., Edelson R. Inhibition of autoimmune disease in a murine model of systemic lupus erythematosus induced by exposure to syngeneic photoactivated lymphocytes. J. Invest. Derm. 94(1):1990;52-57.
27. Cohen I.R., Holoschitz J., van Eden W., Frenkel A. T lymphocyte clones illuminate pathogenesis and effect therapy of experimental arthritis. Arthr. Rheum. 28:1985;841-845.
28. Perez M.I., Edelson R.L., John L., Laroche L., Berger C.L. Inhibition of antiskin allograft immunity induced by infusions with photoinactivated effector T lymphocytes (PET-cells). Yale J. Biol. Med. 62:1989;595-609.
29. Pepino P., Berger C.L., Fuzesia, Panza A., Piesena R.N., Gutierrez C.et al. Primate cardiac allo-and-xenotransplantation: modulation of the immune response with photochemotherapy. Eur. Sur. Res. 21:1989;105-113.
30. Heshmati F, Andreu G, Michel A, Takavoli R, Houssin D. Efficiency of the association of extracorporeal photochemotherapy and cyclosporine in the prevention of heterotopic heart allograft rejection in rat. WAA 5th International Congress, Houston, 9-12 March 1994.
31. Di Renzo M., Rubegni P., De Aloe G., Paulesu L., Pasqui A.L., Andreassi L.et al. Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma. Immunology. 92(1):1997;99-103.
32. Tambur A.R., Ortegel J.W., Morales A., Gebel H.M., Tharp M.D. Extracorporeal photopheresis induces lymphocyte but not monocyte apoptosis. Transplant Proc. 32:2000;747-748.
33. Kadowaki N., Antonenko S., Ho S., Rissoan M.C., Soumelis V., Porcelli S.A.et al. Distinct cytokine profiles of neonatal natural killer T-cells after expansion with subsets of dendritic cells. J. Exp. Med. 193(10):2001;1221-1226.
34. Yoo E.K., Cassin M., Lessin S.R., Rook A. Complete molecular remissionduring biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. J. Am. Acad. Dermatol. 45(2):2001.
35. Nestle F.O., Banchereau J., Hart D. Dendritic cells: On the move from bench to bedside. Nature Med. 7(7):2001;761-765.
36. Zitvogel L., Faure F. L'immunité antitumorale: des concepts à l'immunothérapie active spécifique. Médecine/Sci. 15:1999;939-949.
37. Hanlon D.J., Berger C.L., Edelson R.L. Photoactivated 8-methoxypsoralen treatment causes a peptide-dependent increase in antigen display by transformed lymphocytes. Int. J. Cancer. 78(1):1998;70-75.
38. 2 regulates the migratory capacity of specific DC subsets. Blood. 100(4):2002;1362-1372.
39. Moor A.C., Schmitt I.M., Beijersbergen van Henegouwen G.M., Chimenti S., Edelson R.L., Gasparro F.P. Treatment with 8- MOP and UVA enhances MHC class I synthesis in RMA cells: preliminary results. J. Photochem. Photobiol. 29:1995;193-198.
40. Amigorena S. Présentation antigenique par les cellules dendritiques. Médecine/Sci. 15:1999;931-938.
41. Ingen-Housz-Oro S., Bussel A., Flageul B., Michel L., Dubertret L., Kourilsky P.et al. A prospective study on the evolution of the T-cell repertoire in patients with Sézary syndrome treated by extracorporeal photopheresis. Blood. 100(6):2002;2168-2174.
42. Liu Y.J., Kanzler H., Soumalis V., Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nature Immunol. 2:2001;585-589.
43. Rook A.H., Gottlieb S.L., Wolfe J.T., Vowels B.R., Sood S.S., Niu Z.et al. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Clin. Exp. Immunol. 107(1):1997;16-20.
44. Dippel I.E., Schrag H., Goerdt, Ofanos C.E. Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma. Lancet. 350(9070):1997;32-33.
45. Dall'amico R., Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther. Apher. 6(4):2002;296-304.
46. Tanaka J., Imamura M., Kasai M., Hashino S., Kobayashi S., Noto S.et al. The important balance between cytokines derived from type 1 and type 2 helper T-cells in the control of graft-versus-host disease. Bone Marrow Transplant. 19(6):1997;571-576.
47. Ratanatharathorn V., Ayash L., Lazarus H.M., Fu J., Uberti J.P. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant. 28(2):2001;121-129.
48. Gorgun G., Alcindor T., Rao R., Foss F. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood. 100(3):2002;941-947.
49. Foss F, Chan G, Roberts T, Sprague K, Miller K. Novel pentostatin/extracorporeal photopheresis reduced intensity conditioning regimen: risuls in relapsed/refractory NHL. 44 Annual meeting of American Society of Hematology, 6-10 December 2002, Philadelphia, USA.
50. Shlomchik W.D., Couzens M.S., Tang C.B., McNiff J., Robert M.E., Liu J., Shlomchik, merson S.G. Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells. Science. 285(5426):1999;412-415.
51. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 99(10):2002;3493-3499.
52. Wagner J.E., Barker J.N., DeFor T.E., Baker K.S., Blazer B.R., Eide C.et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and non-malignant disease: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 100(5):2002;1611-1618.
53. Rissoan M.C., Soumelis V., Kadowaki N., Grouard G., Briere F., de Waal Malefyt R.et al. Reciprocal control of T helper cell and dendritic cell differentiation. Sci. Mag. 283(5405):1999;1183-1186.
54. Shlomchik W.D., Couzens M.S., Tang C.B., McNiff J., Robert M.E., Liu J.et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 285(5426):1999;412-415.
55. French L.E., Rook A.H. T-cell clonality and the effect of photopheresis in systemic sclerosis and graft versus host disease. Transfus. Apheresis Sci. 26(3):2002;191-196.
56. Girardi M., Schechner J., Glusac E., Berger C., Edelson R. Transimmunization and the evolution of ectracorporeal photochemotherapy. Transfus. Apheresis Sci. 26(3):2002;181-190.
57. Kohnen S., Hammerstein W. Refsum syndrome in a pair of monocygote. Ophthamologe. 90(5):1993;519-521.
58. Liebichet al. Analysis of polyunsaturated fatty acids in blood serum after fish oil administration. J. Chromatogr. 572:1991;1.
59. Verhoeven N.M., Wanders R.J.A., Poll-The, Saudubray J.M., Jakobs C. The metabolism of phytanic and pristanic acid. J. Inher. Metab. Dis. 21:1998;697-728.
60. Marano R., Soliveri P., Garavaglia B., Antonelli A., Girotti F. A case of Refsum disease with atypical clinical picture in family members. Ital. J. Neurol. Sci. 10(4):1989;451-454.
61. Yamamoto S., Onozu H., Yamada N., Hayasaki S., Watanabe A. Mild retinal changes in a 47-year-old patient with phytanic acid storage disease. Ophthalmologica. 209(5):1995;251-255.
62. Levy R., Verny M., Brault J.I., Gugenheim M., Maisonobe T., Leger J.M. Pauci-symptomatic sensory polyneuropathy in Refsum's disease. Rev. Neurol (Paris). 152(6-7):1996;469-472.
63. Baumgartner M.R., Jansen G.A., Verhoeven N.M., Mooyer P.A., Jakobs C., Roels F.et al. Atypical refsum disease with pipecolic acidemia and abnormal catalase distribution. Ann. Neurol. 47(1):2000;109-113.
64. Tranchant C., Aubourg P., Mohr M., Rocchicciolöi F., Zaenker C., Warter J.M. A new peroxisomal disease with impaired phytanic and pipecolic acid oxidation. Neurology. 43(10):1993;2044-2048.
65. Wanders R.J., Smit W., Heymans H.S., Schutgens R.B., Barth P.G., Schierbeck H.et al. Age-related accumulation of phytanic acid in plasma from patients with the cerebro-hepato-renal (Zellweger) syndrome. Clin. Chim. Acta. 166(1):1987;45-56.
66. Tenbrink H.J., Schor D.S., Kok R.M., Poll B.T., Wanders R.J., Jakobs C. Phytanic acid alpha-oxidation: accumulation of 2-hydroxyphytanic acid and absence of 2-oxophytanic acid in plasma from patients with peroxisomal disorders. J. Lipid Res. 33(10):1992;1449-1457.
67. Gutsche H.U., Siegmund J.B., Hoppmann I. Lipapheresis, an immunoglobulin-spraing treatment for Refsum's disease. Acta Neurol. Scand. 94:1996;103-190.
68. Matsuda Y., Malchesky P.S., Nose Y. Assesment of currently available low density lipoprotein apheresis systems. Artif. Organs. 18:1994;93-99.
69. Straube R., Gäckler D., Thiele A., Musselmann L., Kingreen H., Klingel R. Membrane Differentuial Filtration MDF is Safe and Effective for the Long-Term Treatment of Refsum's disease. Kidney Blood Pressure Res. 23:2000;214-347.